1. Antihypertensive effects of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man;Gavras, H.; Turini, G.A.; Gavras, I.;N Engl J Med,1978
2. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor (SQ14225, captopril) in hypertension patients;Case, D.B.; Atlas, S.A.; Laragh, J.H.; Sealey, J.E.; Sullivan, P.A.; McKinstry, D.N.;Prog Cardiovasc Dis,1978
3. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme;MacGregor, G.A.; Markandu, N.D.; Roulston, J.E.; Jones, J.C.,1979
4. Converting enzyme inhibition with an orally active compound in hypertensive man;Bravo, E.L.; Tarazi, R.C.;Hypertension,1979
5. Inappropriate renin secretion unmasked by captopril (SQ14225) in hypertension of chronic renal failure;Brunner, H.R.; Wauters, J.; McKinstry, D.; Waeber, B.; Turini, G.; Gavras, H.;Lancet,1978